# OnCo record nct06202261 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06202261/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06202261", "NCT06202261" ;
  schema:name "A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer"@en ;
  schema:description "A phase 1/2 trial of TQB2930, TQB3616, Fulvestrant, Capecitabine, Vinorelbine and Eribulin in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06202261/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06202261> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-04-13" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/tqb2930/>, <https://onco.cc/drugs/tqb3616/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/eribulin/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> .